Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria (Overall Cardiovascular Study):~* Diagnosis of T2DM in accordance with American Diabetes Association (ADA) guidelines~* Hemoglobin A1c (A1C) at the start of study participation of 7.0-10.5% (53-91 mmol/mol)~* On stable allowable anti-hyperglycemic agents (AHA) or on no background AHA for at least 8 weeks prior to the study participation~* Body Mass Index (BMI) \> or = to 18.0 kg/m\^2~* Evidence or a history of atherosclerosis involving the coronary, cerebral or peripheral vascular systems~* There is adequate documentation of the objective evidence that the participant has established vascular disease such as investigational site's medical records, copies of such records from other institutions, or a letter from a referring physician that specifically states the diagnosis and date of the most recent occurrence of the qualifying event(s) or procedure(s).~* Male, female not or reproductive potential, or female of reproductive potential who agrees to be abstinent from heterosexual activity or agrees to use or have their partner use 2 acceptable methods of contraception~Exclusion Criteria (Overall Cardiovascular Study):~* Previous randomization into this trial~* Experiencing a cardiovascular event (myocardial infarction or stroke) or undergoing coronary angioplasty or peripheral intervention procedure between the Screening Visit and randomization~* Undergoing any cardiovascular surgery (valvular surgery) within 3 months of study participation~* Planned revascularization or peripheral intervention procedure or other cardiovascular surgery~* New York Heart Association (NYHA) IV heart failure at study participation~* History of type 1 diabetes mellitus or a history of ketoacidosis~Key Inclusion Criteria for the 3 Glycemic Sub-studies:~1. Insulin With or Without Metformin Sub-study: Stable doses of insulin (\>=20 units/day, with variations up to 10% in the daily dose permitted) with or without metformin (\>=1500 mg/day) for at least 8 weeks prior to the time of the Screening Visit (V1) and during the period between the Screening Visit (V1) and randomization.~2. Sulfonylurea (SU) Monotherapy Sub-study: Participants receiving a stable dose of SU monotherapy for at least 8 weeks prior to the time of the Screening Visit (V1) and during the period between the Screening Visit (V1) and randomization.~3. Metformin with SU Sub-study: Participants receiving a stable dose metformin (≥1500 mg/day) with a SU for at least 8 weeks prior to the time of the Screening Visit (V1) and during the period between the Screening Visit (V1) and randomization.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin, 15 mg (Type: EXPERIMENTAL): Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years
- Ertugliflozin, 5 mg (Type: EXPERIMENTAL): Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years

Based on this trial design, predict the completion outcome and termination type (if applicable).